{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T23:11:42Z","timestamp":1649200302709},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1097\/mjt.0b013e31824ea644","type":"journal-article","created":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T18:16:39Z","timestamp":1348596999000},"page":"267-274","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Impact of Temporary Therapy Interruptions on Anticoagulation Control in Patients Treated With Warfarin"],"prefix":"10.1097","volume":"20","author":[{"given":"Melanie L.","family":"Boros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy M.","family":"Rybarczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Gallegos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob P.","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210202","doi-asserted-by":"crossref","first-page":"299S","DOI":"10.1378\/chest.08-0675","article-title":". The perioperative management of antithrombotic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition).","volume":"133","author":"Douketis","year":"2008","journal-title":"Chest"},{"key":"R2-8-20210202","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":". Pharmacology and management of the vitamin k antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition).","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"R5-8-20210202","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1345\/aph.1A431","article-title":". Factors affecting warfarin therapy following cardiac valve surgery.","volume":"36","author":"Lee","year":"2002","journal-title":"Ann Pharmacother"},{"key":"R6-8-20210202","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1345\/aph.1G407","article-title":". Increased sensitivity to warfarin after heart valve replacement.","volume":"40","author":"Rahman","year":"2006","journal-title":"Ann Pharmacother"},{"key":"R7-8-20210202","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1365-2796.2007.01913.x","article-title":". Clinical factors affecting sensitivity to warfarin when restarted after surgery.","volume":"263","author":"Schulman","year":"2008","journal-title":"J Intern Med"},{"key":"R8-8-20210202","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":". Systematic overview of warfarin and its drug and food interactions.","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"key":"R9-8-20210202","first-page":"184","article-title":"Interactions between warfarin and herbal products, minerals, and vitamins: a pharmacists guide.","volume":"54","author":"Stenton","year":"2001","journal-title":"Can J Hosp Pharm"},{"key":"R10-8-20210202","first-page":"635","article-title":"Warfarin therapy: evolving strategies in anticoagulation.","volume":"59","author":"Horton","year":"1999","journal-title":"Am Fam Physician"},{"key":"R12-8-20210202","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","article-title":". Association between CYP2C9 genetic variant and anticoagulation-related outcomes during warfarin therapy.","volume":"287","author":"Higashi","year":"2002","journal-title":"JAMA"},{"key":"R13-8-20210202","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","article-title":". Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.","volume":"352","author":"Rieder","year":"2005","journal-title":"N Engl J Med"},{"key":"R14-8-20210202","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clpt.2005.11.011","article-title":". Influence of coagulation factor, vitamin k epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.","volume":"79","author":"Aquilante","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R15-8-20210202","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/bmj.284.6317.702","article-title":"Therapeutic control of anticoagulant treatment.","volume":"284","author":"Duxbury","year":"1982","journal-title":"Br Med J"},{"key":"R16-8-20210202","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ahj.2008.02.009","article-title":". Is long-term pharmacist-managed anticoagulation service efficient A pragmatic randomized controlled trial.","volume":"156","author":"Lolonde","year":"2008","journal-title":"Am Heart J"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e31824ea644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:37:06Z","timestamp":1620963426000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201305000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31824ea644","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}